卵巢癌胚系与体细胞基因检测的临床意义:BRCA及 beyond——PERSONA-Ovary 试验
PERSONA-Ovary 前瞻性观察研究纳入 320 例卵巢癌患者,评估未选择性多基因胚系检测的可行性与胚系-体细胞 BRCA 一致性。胚系致病/可能致病变异检出率 29.7%(95% CI 24.7-35.0),检测信息率 100%,中位周转时间 221 天(IQR 173-284)。胚系-体细胞 BRCA 一致性 94.0%(κ=0.82)。
要点
- 未选择性胚系多基因 panel 检测在常规卵巢癌诊疗中技术可行且临床可提供信息。
- 胚系致病/可能致病变异检出率为 29.7%,支持将胚系检测整合入 contemporary 卵巢癌管理。
- 胚系先行策略可最大化遗传性癌症检出,但需专门分子工作流程以确保临床可操作的周转时间。
核心结论
- 未选择性胚系多基因 panel 检测在常规卵巢癌诊疗中技术可行且临床可提供信息,致病/可能致病变异检出率 29.7%,支持将胚系检测整合入当代卵巢癌管理。
研究设计与样本
- 前瞻性观察研究,连续纳入 2018 年 7 月至 2021 年 9 月在一家三级癌症中心治疗的卵巢癌患者,共 320 例,采用下一代测序进行胚系多基因 panel 检测。
主要发现
- 320 例中 95 例(29.7%,95% CI 24.7-35.0)检出致病/可能致病变异,其中 81 例(85.3%,95% CI 76.5-91.7)携带卵巢癌易感基因突变,包括 60 例 BRCA 改变(63.2%,BRCA1 n=43,BRCA2 n=17)。
- 胚系检测在所有患者中均可提供信息(100%),中位周转时间 221 天(IQR 173-284),随研究阶段显著改善(p<0.001)。
- 298 例(93.1%)有肿瘤 BRCA 检测结果,胚系-体细胞一致性为 94.0%(κ=0.82,95% CI 0.72-0.90)。
- 胚系先行联合反射性肿瘤检测以较少检测实现完全检出;肿瘤先行策略所需检测最少(366 vs 596),但漏检 2 例胚系 BRCA 携带者(检出率 96.3%)。
临床怎么用
- 可将未选择性胚系多基因 panel 检测整合入常规卵巢癌诊疗,以识别遗传性癌症风险。
- 选择胚系先行或肿瘤先行策略时需权衡检出率与检测数量,并建立专门分子工作流程以确保临床可操作的周转时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The PERSONA-Ovary study evaluated germline pathogenic/likely-pathogenic variant prevalence, feasibility of unselected multigene testing integration in routine clinical care, and germline-somatic BRCA concordance in ovarian cancer patients. METHODS: We conducted a prospective observational study of consecutive ovarian carcinoma patients treated at a tertiary-cancer care center, between July 2018 and September 2021. Germline multigene panel testing was performed using next-generation sequencing. Feasibility was assessed by informative rate and turnaround time. Germline-somatic concordance was assessed in patients with paired tumor BRCA results. RESULTS: Among 320 patients, pathogenic/likely-pathogenic variants were identified in 95 (29.7%, 95% CI 24.7-35.0); 81 (85.3%, 95% CI 76.5-91.7) carried mutations in ovarian cancer susceptibility genes, including 60 with BRCA alterations (63.2%, BRCA1 n=43, BRCA2 n=17). Germline testing was informative in all patients (100%). Median turnaround time was 221days (IQR 173-284), improving significantly across study periods (p<0.001). Tumor BRCA testing was available in 298 patients (93.1%), with germline-somatic concordance of 94.0% (κ=0.82, 95% CI 0.72-0.90). A germline-first strategy with reflex tumor testing achieved complete detection with fewer assays than parallel testing; a tumor-first strategy required the fewest assays (366 vs 596) but missed two germline BRCA carriers (detection rate of 96.3%). CONCLUSION: Unselected germline multigene panel testing was technically feasible and clinically informative in routine ovarian cancer care. Pathogenic/likely-pathogenic variants were identified in 29.7% of patients, supporting germline testing integration into contemporary ovarian cancer management. Although germline-first strategies maximize hereditary cancer detection, dedicated molecular workflows remain necessary to ensure clinically actionable turnaround times.
引用
- Betella I, Bonetti E, Ribero L, et al. Clinical implications of germline and somatic genetic testing in ovarian carcinoma: BRCA and beyond. The PERSONA-Ovary trial. Gynecol Oncol. 2026. PMID: 42887399. doi:10.1016/j.ygyno.2026.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。